A rationally designed class of mTORC1 inhibitors combines the selectivity of rapamycin with the potency of mTOR kinase inhibitors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Oncogene Open Access 01 June 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Saxton, R. A. & Sabatini, D. M. Cell 168, 960–976 (2017).
Benjamin, D., Colombi, M., Moroni, C. & Hall, M. N. Nat. Rev. Drug Discov. 10, 868–880 (2011).
Lee, B. J. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-021-00813-7 (2021).
Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P. & Blenis, J. Proc. Natl. Acad. Sci. USA 105, 17414–17419 (2008).
Feldman, M. E. et al. PLoS Biol. 7, e38 (2009).
Thoreen, C. C. et al. J. Biol. Chem. 284, 8023–8032 (2009).
Dowling, R. J. et al. Science 328, 1172–1176 (2010).
Rodrik-Outmezguine, V. S. et al. Nature 534, 272–276 (2016).
Sarbassov, D. D. et al. Mol. Cell 22, 159–168 (2006).
Kennedy, B. K. & Lamming, D. W. Cell Metab. 23, 990–1003 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Thoreen, C.C. Split-personality inhibitors. Nat Chem Biol 17, 1012–1013 (2021). https://doi.org/10.1038/s41589-021-00820-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-021-00820-8